Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

• Status: Recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OptiSkin Medical
• Collaborator: Regeneron Pharmaceuticals

Criteria

Inclusion Criteria:

• ≥18 years of age

• Atopic dermatitis (AD) affecting ≥10% body surface area (BSA) at baseline

• IGA score ≥3, on the IGA scale of 0-4 at baseline

• Eczema Area and Severity Index (EASI) score of ≥16 at baseline

Exclusion Criteria:

• Prior treatment with Dupilumab (REGN668/SAR231893)

• Treatment with TCS or topical calcineurin inhibitors (TCI) within 2 weeks before the baseline visit

• Bodyweight <30 kg (65lb) at Baseline

• Known or suspected immunodeficiency including human immunodeficiency virus (HIV) infection

• Pregnancy, breastfeeding or planning to become pregnant or breastfeed during the study